Captopril as a modifier of the arachidonate cascade of rat platelets

A. Gecse, G. Telegdy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The lipoxygenase pathway of arachidonate cascade in the platelets of spontaneously hypertensive rats has been found to be significantly higher than in normotensive animals. Repeated oral administration of Captopril (in drinking water - 200 mg/100 ml) for 14 days resulted in an elevation in the activity of arachidonate cascade in the platelets of treated rats. At the same time the Captopril treatment induced the formation of 12-hydroxy-heptadecatrienoic acid (12-HHT), which molecule is known to be a potent prostacyclin (PGI2) releaser and/or synthesis inducer. PGI2 is one of the most potent vasodilatator molecule in living organisms. The in vitro experiments in rat platelets suggest, that very low doses of Captopril (10-12 to 10-10 M) result in a significantly elevated 12-HHT synthesis. Captopril might act through the 12-HHT PGI2 mechanism, resulting in blood pressure reduction. The lipoxygenase pathway of platelets, the formation of 12-hydroxyeicosatetraenoic acid (12-HETE), was significantly elevated in vitro in the presence of low dose of Captocril (10-11 and 10-10).

Original languageEnglish
Pages (from-to)201-208
Number of pages8
JournalAgents and Actions
Volume38
Issue numberSUPPL. III
Publication statusPublished - 1992

Fingerprint

Captopril
Epoprostenol
Platelets
Hydroxy Acids
Rats
Blood Platelets
Lipoxygenase
Acids
Arachidonate Lipoxygenases
Hydroxyeicosatetraenoic Acids
Molecules
Blood pressure
Inbred SHR Rats
Drinking Water
Oral Administration
Animals
Blood Pressure
Experiments
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology

Cite this

Captopril as a modifier of the arachidonate cascade of rat platelets. / Gecse, A.; Telegdy, G.

In: Agents and Actions, Vol. 38, No. SUPPL. III, 1992, p. 201-208.

Research output: Contribution to journalArticle

@article{9cc6e5196af840efbf007dc9d3a00ada,
title = "Captopril as a modifier of the arachidonate cascade of rat platelets",
abstract = "The lipoxygenase pathway of arachidonate cascade in the platelets of spontaneously hypertensive rats has been found to be significantly higher than in normotensive animals. Repeated oral administration of Captopril (in drinking water - 200 mg/100 ml) for 14 days resulted in an elevation in the activity of arachidonate cascade in the platelets of treated rats. At the same time the Captopril treatment induced the formation of 12-hydroxy-heptadecatrienoic acid (12-HHT), which molecule is known to be a potent prostacyclin (PGI2) releaser and/or synthesis inducer. PGI2 is one of the most potent vasodilatator molecule in living organisms. The in vitro experiments in rat platelets suggest, that very low doses of Captopril (10-12 to 10-10 M) result in a significantly elevated 12-HHT synthesis. Captopril might act through the 12-HHT PGI2 mechanism, resulting in blood pressure reduction. The lipoxygenase pathway of platelets, the formation of 12-hydroxyeicosatetraenoic acid (12-HETE), was significantly elevated in vitro in the presence of low dose of Captocril (10-11 and 10-10).",
author = "A. Gecse and G. Telegdy",
year = "1992",
language = "English",
volume = "38",
pages = "201--208",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",
number = "SUPPL. III",

}

TY - JOUR

T1 - Captopril as a modifier of the arachidonate cascade of rat platelets

AU - Gecse, A.

AU - Telegdy, G.

PY - 1992

Y1 - 1992

N2 - The lipoxygenase pathway of arachidonate cascade in the platelets of spontaneously hypertensive rats has been found to be significantly higher than in normotensive animals. Repeated oral administration of Captopril (in drinking water - 200 mg/100 ml) for 14 days resulted in an elevation in the activity of arachidonate cascade in the platelets of treated rats. At the same time the Captopril treatment induced the formation of 12-hydroxy-heptadecatrienoic acid (12-HHT), which molecule is known to be a potent prostacyclin (PGI2) releaser and/or synthesis inducer. PGI2 is one of the most potent vasodilatator molecule in living organisms. The in vitro experiments in rat platelets suggest, that very low doses of Captopril (10-12 to 10-10 M) result in a significantly elevated 12-HHT synthesis. Captopril might act through the 12-HHT PGI2 mechanism, resulting in blood pressure reduction. The lipoxygenase pathway of platelets, the formation of 12-hydroxyeicosatetraenoic acid (12-HETE), was significantly elevated in vitro in the presence of low dose of Captocril (10-11 and 10-10).

AB - The lipoxygenase pathway of arachidonate cascade in the platelets of spontaneously hypertensive rats has been found to be significantly higher than in normotensive animals. Repeated oral administration of Captopril (in drinking water - 200 mg/100 ml) for 14 days resulted in an elevation in the activity of arachidonate cascade in the platelets of treated rats. At the same time the Captopril treatment induced the formation of 12-hydroxy-heptadecatrienoic acid (12-HHT), which molecule is known to be a potent prostacyclin (PGI2) releaser and/or synthesis inducer. PGI2 is one of the most potent vasodilatator molecule in living organisms. The in vitro experiments in rat platelets suggest, that very low doses of Captopril (10-12 to 10-10 M) result in a significantly elevated 12-HHT synthesis. Captopril might act through the 12-HHT PGI2 mechanism, resulting in blood pressure reduction. The lipoxygenase pathway of platelets, the formation of 12-hydroxyeicosatetraenoic acid (12-HETE), was significantly elevated in vitro in the presence of low dose of Captocril (10-11 and 10-10).

UR - http://www.scopus.com/inward/record.url?scp=0026793210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026793210&partnerID=8YFLogxK

M3 - Article

C2 - 1462859

AN - SCOPUS:0026793210

VL - 38

SP - 201

EP - 208

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

IS - SUPPL. III

ER -